131Iodine-DEM TACE vs . conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment

Journal of Gastrointestinal Oncology

article

Yu Ma¹  Ligeng Duan³  Lin Li⁴  Wusheng Lu⁵  Bo Li⁵  Xiaoli Chen² 

[1] Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University;Department of General Surgery, West China Hospital, Sichuan University;Department of Emergency, West China Hospital, Sichuan University;Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University;Department of Liver Surgery, West China Hospital, Sichuan University

关键词: Transcatheter arterial chemoembolization (TACE);    131 Iodine;    anticancer;    hepatocellular carcinoma (HCC);    microspheres;   

DOI  :  10.21037/jgo-21-105

学科分类：肿瘤学

来源: Pioneer Bioscience Publishing Company

【 摘 要 】

Background: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) with 131 iodine-doxorubicin-eluting gelatin microspheres ( 131 I-DEM TACE) compared with conventional TACE (cTACE) with polyvinyl alcohol foam (PVA) embolization microspheres. Methods: A total of 22 patients diagnosed with hepatocellular carcinoma were equally divided into 2 groups. The patients who underwent TACE with 131 I-DEM (25.7×10 7 Bq of 131iodine and 10 mg of doxorubicin) were compared to controls who received cTACE with PVA embolization microspheres. Therapeutic effects were evaluated by the tumor regression rates, levels of alpha-fetoprotein in serum, survival rates, and complications. Results: The operative complications of the 2 groups were not significantly different (P=0.753). The radioactivity ratio of the tumor to the liver was approximately 4.1:1 for the 131 I-DEM TACE group. In the 131 I-DEM TACE group, 54.5% of patients achieved tumor regression of more than 50%, compared to 36.6% of patients in the cTACE group. AFP levels in serum declined in 100% of patients in the 131 I-DEM TACE group and 50% of patients in the cTACE group. The median survival time of the patients was 12.0±3.3 months for the 131 I-DEM TACE group and 10.0±3.3 months for the cTACE group. There were no significant differences in survival between the 2 groups (P=0.414). Conclusions: 131 I-DEM may become a potential radiochemoembolization agent to treat patients with unresectable hepatocellular carcinoma through TACE.

【 授权许可】

Unknown